Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 5, 2009, Pages 437-444

  Davies, Helen E ^a   Sadler, Ross S ^b   Bielsa, Silvia ^c   Maskell, Nicholas A ^d   Rahman, Najib M ^a   Davies, Robert J O ^a   Ferry, Berne L ^b   Lee, Y C Gary ^a,c,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Biomarker; Mesothelin; Mesothelioma; Pleura; Pleural effusion

Indexed keywords

BIOLOGICAL MARKER; MESOTHELIN;

AGED; ARTICLE; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LUNG CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; PLEURA EFFUSION; PLEURA FLUID; PLEURODESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE DIAGNOSIS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AGED; BACTERIAL INFECTIONS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 69249086595     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200811-1729OC     Document Type: Article

References (43)

1. Light RW, Lee YCG. Textbook of pleural diseases, 2nd ed. London: Hodder Arnold; 2008.
2. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin Chest Med 2006;27:335-354.
3. Health & Safety Executive. Mesothelioma mortality in Great Britain: estimating the future burden. London: HSE Publications; 2003. pp. 1-26. Available from: http://www.hse.gov.uk/statistics/causdis/proj6801.pdf
4. Lee YC. Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax 2007;62:561-562.
5. Wick MR. Pathology: cytology. In Light RW, Lee YCG, editors. Textbook of pleural diseases. London: Hodder Arnold; 2008. pp. 293-313.
6. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006;1:172-174.
7. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-576.
8. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-272.
9. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616.
10. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer 2005;49:S109-S111.
11. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-1160.
12. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-443.
13. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albeda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009;179:950-954.
14. Davies HE, Sadler RS, Manners CE, Davies RJO, Ferry BL, Lee YCG. The diagnostic accuracy and reproducibility of pleural fluid levels of mesothelin in unselected patients with pleural effusions [abstract 61]. Presented at the 9th International Conference of the International Mesothelioma Interest Group, Amsterdam, The Netherlands, September 25-27, 2008.
15. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJO, Ferry BL, Lee YCG. The clinical role and reliability of pleural fluid mesothelin in undiagnosed pleural effusions [abstract]. Proc Am Thorac Soc 2009;179:A3934.
16. Davies HE, Sadler RS, Manners CE, Davies RJO, Ferry BL, Lee YCG. Pleural fluid mesothelin levels: diagnostic accuracy, reproducibility and reliability after pleurodesis [abstract 48]. Thorax 2008;63(SupplVII):S107.
17. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004;170:377-382.
18. Rahman NM, Mishra EK, Davies HE, Davies RJ, Lee YC. Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose. Am J Respir Crit Care Med 2008;178:483-490.
19. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003;58:ii8-ii17.
20. Filie AC, Copel C, Wilder AM, Abati A. Individual specimen triage of effusion samples: an improvement in the standard of practice, or a waste of resources? Diagn Cytopathol 2000;22:7-10.
21. Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol 2005;32:137-144.
22. Davies HE, Lee YCG. Pleural effusion, empyema and pneumothorax. In Albert RK, Spiro SG, Jett JR, editors. Clinical respiratory medicine. New York: Elsevier; 2008.
23. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-513.
24. Davies CW, Gleeson FV, Davies RJ. BTS guidelines for the management of pleural infection. Thorax 2003;58:ii18-ii28.
25. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999;107:262-267.
26. Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, Ehrenstein MR, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 2002;99:16969-16974.
27. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
28. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
29. Park SH, Goo JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 2004;5:11-18.
30. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.
31. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62:ii1-ii19.
32. Huncharek M. Exporting asbestos: disease and policy in the developing world. J Public Health Policy 1993;14:51-65.
33. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 2005;49:S3-S8.
34. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
35. World Health Organization. Elimination of asbestos-related disease [policy paper]. http://www.who.int/occupational-health/publications? asbestosrelateddisease/en/ 2006;1-4.
36. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Cottman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
37. Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993;269:1123-1126.
38. Goldberg EM, Simunovic LM, Drake SL, Mueller WF Jr, Verrill HL. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer. Hybridoma 1989;8:569-575.
39. Jain S, Bhojwani AG, Mellon JK. Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J 2002;78:646-650.
40. Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, de Paoli M, Plebani M, Tulassay Z. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 2008;8:194.
41. Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 1999;29:550-555.
42. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002;122:1018-1027.
43. Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 2000;161:595-600.